急性心肌梗死合并心源性休克中并发脓毒症的诊断:15年全国时间趋势、管理与结局
该观察性研究基于美国20%分层抽样的社区医院2000-2014年数据,纳入444,253例急性心肌梗死合并心源性休克(AMI-CS)成人住院患者,其中27,057例(6%)并发脓毒症。脓毒症组合并症更多、非心脏多器官衰竭比例更高(92% vs 69%,p<0.001),接受冠状动脉造影(65% vs 68%)和经皮冠状动脉介入治疗(43% vs 48%)更少,机械循环支持(48% vs 45%)、有创机械通气(65% vs 41%)和急性血液透析(12% vs 3%)使用更多(p<0.001)。脓毒症组住院死亡率更高(44.3% vs 38.1%;aOR 1.21;95%CI 1.18-1.25;p<0.001),住院时间更长(14.0天[7-24天] vs 7.0天[3-12天]),住院费用更高(176.0千美元[85-331] vs 77.0千美元[36-147]),出院回家更少(22% vs 44%),出院至专业护理机构更多(51% vs 28%)(均p<0.001)。作者认为并发脓毒症与更高的死亡率和发病率相关,凸显早期识别与混合性休克整合管理的必要性。
要点
- AMI-CS住院患者中6%(27,057/444,253)并发脓毒症,脓毒症组非心脏多器官衰竭92% vs 69%(p<0.001)。
- 脓毒症组住院死亡率44.3% vs 38.1%(aOR 1.21;95%CI 1.18-1.25;p<0.001)。
- 脓毒症组接受冠状动脉造影65% vs 68%、PCI 43% vs 48%更少,机械循环支持48% vs 45%、有创机械通气65% vs 41%、急性血液透析12% vs 3%更多(p<0.001)。
- 2014年较2000年脓毒症患病率在STEMI中从0.5%升至11.5%(aOR 11.71;95%CI 9.7-14.0),在NSTEMI中aOR 24.6(95%CI 16.4-36.7)(均p<0.001)。
- 脓毒症组住院时间14.0天(7-24天)vs 7.0天(3-12天),住院费用176.0千美元(85-331)vs 77.0千美元(36-147),出院回家22% vs 44%,出院至专业护理机构51% vs 28%(均p<0.001)。
适用人群与场景
- 美国社区医院2000-2014年20%分层样本中年龄>18岁的急性心肌梗死合并心源性休克(AMI-CS)住院成人,分为并发脓毒症与不并发脓毒症两组。
研究设计与关键结果
- 观察性研究,基于美国20%分层抽样的社区医院2000-2014年数据,纳入444,253例AMI-CS成人住院患者,其中27,057例(6%)并发脓毒症。
- 脓毒症组合并症更多,非心脏多器官衰竭发生率92% vs 69%(p<0.001)。
- 2014年较2000年,脓毒症患病率在STEMI中从0.5%升至11.5%(aOR 11.71;95%CI 9.7-14.0),在NSTEMI中aOR 24.6(95%CI 16.4-36.7)(均p<0.001)。
- 脓毒症组接受冠状动脉造影65% vs 68%、PCI 43% vs 48%更少,机械循环支持48% vs 45%、有创机械通气65% vs 41%、急性血液透析12% vs 3%更多(p<0.001)。
- 脓毒症组住院死亡率44.3% vs 38.1%(aOR 1.21;95%CI 1.18-1.25;p<0.001)。
- 脓毒症组住院时间14.0天(7-24天)vs 7.0天(3-12天),住院费用176.0千美元(85-331)vs 77.0千美元(36-147),出院回家22% vs 44%,出院至专业护理机构51% vs 28%(均p<0.001)。
证据类型、等级与局限
- 证据类型:观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,AMI-CS中并发脓毒症与更高的死亡率和发病率相关,凸显早期识别与混合性休克整合管理的必要性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Mixed cardiogenic-septic shock is common and associated with high mortality. There are limited contemporary data on concomitant sepsis in acute myocardial infarction complicated by cardiogenic shock (AMI-CS).
DESIGN: Observational study.
SETTING: Twenty percent stratified sample of all community hospitals (2000-2014) in the United States.
PARTICIPANTS: Adults (> 18 yr) with AMI-CS with and without concomitant sepsis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Outcomes of interest included inhospital mortality, development of noncardiac organ failure, complications, utilization of guideline-directed procedures, length of stay, and hospitalization costs. Over 15 years, 444,253 AMI-CS admissions were identified, of which 27,057 (6%) included sepsis. The sepsis cohort had more comorbidities and had higher rates of noncardiac multiple organ failure (92% vs 69%) (all p < 0.001). In 2014, compared with 2000, the prevalence of sepsis increased from 0.5% versus 11.5% with an adjusted odds ratio (aOR) 11.71 (95% CI, 9.7-14.0) in ST-segment elevation myocardial infarction and 24.6 (CI, 16.4-36.7) (all p < 0.001) in non-ST segment elevation myocardial infarction. The sepsis cohort received fewer cardiac interventions (coronary angiography [65% vs 68%], percutaneous coronary intervention [43% vs 48%]) and had greater use of mechanical circulatory support (48% vs 45%) and noncardiac support (invasive mechanical ventilation [65% vs 41%] and acute hemodialysis [12% vs 3%]) (p < 0.001). The sepsis cohort had higher inhospital mortality (44.3% vs 38.1%; aOR, 1.21; 95% CI, 1.18-1.25; p < 0.001), longer length of stay (14.0 d [7-24 d] vs 7.0 d [3-12 d]), greater hospitalization costs (×1,000 U.S. dollars) ($176.0 [$85-$331] vs $77.0 [$36-$147]), fewer discharges to home (22% vs 44%) and more discharges to skilled nursing facilities (51% vs 28%) (all p < 0.001).
CONCLUSIONS: In AMI-CS, concomitant sepsis is associated with higher mortality and morbidity highlighting the need for early recognition and integrated management of mixed shock.
参考来源
- Jentzer JC, Bhat AG, Patlolla SH, et al. Concomitant Sepsis Diagnoses in Acute Myocardial Infarction-Cardiogenic Shock: 15-Year National Temporal Trends, Management, and Outcomes. Crit Care Explor. 2022. PMID: 35141527. doi:10.1097/CCE.0000000000000637
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。